Literature DB >> 30684642

Complex, coordinated and highly regulated changes in placental signaling and nutrient transport capacity in IUGR.

Stephanie Chassen1, Thomas Jansson2.   

Abstract

The most common cause of intrauterine growth restriction (IUGR) in the developed world is placental insufficiency, a concept often used synonymously with reduced utero-placental and umbilical blood flows. However, placental insufficiency and IUGR are associated with complex, coordinated and highly regulated changes in placental signaling and nutrient transport including inhibition of insulin and mTOR signaling and down-regulation of specific amino acid transporters, Na+/K+-ATPase, the Na+/H+-exchanger, folate and lactate transporters. In contrast, placental glucose transport capacity is unaltered and Ca2+-ATPase activity and the expression of proteins involved in placental lipid transport are increased in IUGR. These findings are not entirely consistent with the traditional view that the placenta is dysfunctional in IUGR, but rather suggest that the placenta adapts to reduce fetal growth in response to an inability of the mother to allocate resources to the fetus. This new model has implications for the understanding of the mechanisms underpinning IUGR and for the development of intervention strategies.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Fetal development; Fetal growth restriction; Human; Maternal-fetal exchange; Placental transport; Syncytiotrophoblast

Mesh:

Substances:

Year:  2019        PMID: 30684642      PMCID: PMC6650384          DOI: 10.1016/j.bbadis.2018.12.024

Source DB:  PubMed          Journal:  Biochim Biophys Acta Mol Basis Dis        ISSN: 0925-4439            Impact factor:   5.187


  7 in total

1.  Nobiletin Inhibits Hypoxia-Induced Placental Damage via Modulating P53 Signaling Pathway.

Authors:  Meng-Ling Zhang; Qian Yang; Yan-Di Zhu; Ya-Di Zhang; Rui Zhang; Jian Liu; Xiao-Yan Zhao; Qin-Yu Dang; Dong-Xu Huang; Ming-Yuan Zhang; Yu-Chen Wei; Zhuo Hu; Xia-Xia Cai; Li-Fang Gao; Yang Shan; Huan-Ling Yu
Journal:  Nutrients       Date:  2022-06-01       Impact factor: 6.706

Review 2.  Placental Function and the Development of Fetal Overgrowth and Fetal Growth Restriction.

Authors:  Jerad H Dumolt; Theresa L Powell; Thomas Jansson
Journal:  Obstet Gynecol Clin North Am       Date:  2021-06       Impact factor: 2.838

3.  Vasoactive Intestinal Peptide induces glucose and neutral amino acid uptake through mTOR signalling in human cytotrophoblast cells.

Authors:  Fatima Merech; Elizabeth Soczewski; Vanesa Hauk; Daniel Paparini; Rosanna Ramhorst; Daiana Vota; Claudia Pérez Leirós
Journal:  Sci Rep       Date:  2019-11-20       Impact factor: 4.379

4.  Tadalafil Treatment of Mice with Fetal Growth Restriction and Preeclampsia Improves Placental mTOR Signaling.

Authors:  Kayo Tanaka; Hiroaki Tanaka; Ryota Tachibana; Kento Yoshikawa; Takuya Kawamura; Sho Takakura; Hiroki Takeuchi; Tomoaki Ikeda
Journal:  Int J Mol Sci       Date:  2022-01-27       Impact factor: 5.923

5.  Down-regulation of placental Cdc42 and Rac1 links mTORC2 inhibition to decreased trophoblast amino acid transport in human intrauterine growth restriction.

Authors:  Thomas Jansson; Marisol Castillo-Castrejon; Madhulika B Gupta; Theresa L Powell; Fredrick J Rosario
Journal:  Clin Sci (Lond)       Date:  2020-01-17       Impact factor: 6.124

Review 6.  Curcumin: Could This Compound Be Useful in Pregnancy and Pregnancy-Related Complications?

Authors:  Tiziana Filardi; Rosaria Varì; Elisabetta Ferretti; Alessandra Zicari; Susanna Morano; Carmela Santangelo
Journal:  Nutrients       Date:  2020-10-17       Impact factor: 5.717

7.  Differential Expression of Glucose Transporter Proteins GLUT-1, GLUT-3, GLUT-8 and GLUT-12 in the Placenta of Macrosomic, Small-for-Gestational-Age and Growth-Restricted Foetuses.

Authors:  Paweł Jan Stanirowski; Dariusz Szukiewicz; Agata Majewska; Mateusz Wątroba; Michał Pyzlak; Dorota Bomba-Opoń; Mirosław Wielgoś
Journal:  J Clin Med       Date:  2021-12-13       Impact factor: 4.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.